Messenger RNA Therapy for Female Reproductive Health

Mol Pharm. 2024 Feb 5;21(2):393-409. doi: 10.1021/acs.molpharmaceut.3c00803. Epub 2024 Jan 8.

Abstract

Female reproductive health has traditionally been an underrepresented area of research in the drug delivery sciences. This disparity is also seen in the emerging field of mRNA therapeutics, a class of medicines that promises to treat and prevent disease by upregulating protein expression in the body. Here, we review advances in mRNA therapies through the lens of improving female reproductive health. Specifically, we begin our review by discussing the fundamental structure and biochemical modifications associated with mRNA-based drugs. Then, we discuss various packaging technologies, including lipid nanoparticles, that can be utilized to protect and transport mRNA drugs to target cells in the body. Last, we conclude our review by discussing the usage of mRNA therapy for addressing pregnancy-related health and vaccination against sexually transmitted diseases in women. Of note, we also highlight relevant clinical trials using mRNA for female reproductive health while also providing their corresponding National Clinical Trial identifiers. In undertaking this review, our aim is to provide a fundamental background understanding of mRNA therapy and its usage to specifically address female health issues with an overarching goal of providing information toward addressing gender disparity in certain aspects of health research.

Keywords: female health; lipid nanoparticles; mRNA therapies; pregnancy; sexually transmitted infections.

Publication types

  • Review

MeSH terms

  • Female
  • Humans
  • Pregnancy
  • RNA, Messenger / genetics
  • Reproductive Health*
  • Sexually Transmitted Diseases* / prevention & control

Substances

  • RNA, Messenger